司美格鲁肽改善肥胖相关HFpEF患者NYHA功能分级:STEP-HFpEF项目分析
STEP-HFpEF项目预设汇总分析纳入2项国际双盲随机试验共1145例肥胖相关HFpEF患者,随机接受每周一次司美格鲁肽2.4 mg或安慰剂治疗52周。结果显示司美格鲁肽组NYHA功能分级改善比例更高(32.6% vs 21.5%),恶化比例更低(2.09% vs 5.24%),且在各基线NYHA分级亚组中一致改善症状、运动能力和体重。
要点
- 司美格鲁肽52周时NYHA功能分级改善率32.6% vs 安慰剂21.5%,恶化率2.09% vs 5.24%。
- 各基线NYHA分级亚组中司美格鲁肽一致改善KCCQ-CSS、6MWD、体重及炎症和充血生物标志物。
- NYHA III/IV级患者健康状态改善幅度更大(KCCQ-CSS提高10.5分 vs II级6.0分,交互P=0.06)。
核心结论
- 在肥胖相关HFpEF患者中,司美格鲁肽治疗52周后NYHA功能分级恶化者更少、改善者更多。
- 司美格鲁肽在所有NYHA功能分级类别中一致改善心衰相关症状、体力受限和运动功能,并降低体重及炎症和充血生物标志物。
- NYHA III/IV级患者健康状态改善尤为显著。
研究设计与样本
- STEP-HFpEF项目的预设汇总分析,汇总2项国际双盲随机试验(STEP-HFpEF和STEP-HFpEF DM)。
- 共随机1145例肥胖相关HFpEF患者,接受每周一次司美格鲁肽2.4 mg或安慰剂治疗52周。
- 本分析关注基线至52周NYHA功能分级变化,并按基线NYHA分级评估双主要、确证次要及部分探索性终点。
主要发现
- 司美格鲁肽组较安慰剂组更多患者NYHA功能分级改善(32.6% vs 21.5%;OR 2.20,95%CI 1.62-2.99,P<0.001)。
- 司美格鲁肽组较安慰剂组更少患者NYHA功能分级恶化(2.09% vs 5.24%;OR 0.36,95%CI 0.19-0.70,P=0.003)。
- 司美格鲁肽改善KCCQ-CCS在各NYHA分级类别中一致,III/IV级提高10.5分(95%CI 6.6-14.4),II级提高6.0分(95%CI 3.4-8.6),交互P=0.06。
- 体重降低幅度在各基线NYHA分级类别中相似:II级-8.4%(95%CI -9.4%至-7.3%),III/IV级-8.3%(95%CI -9.9%至-6.8%),交互P=0.96。
- 司美格鲁肽在各NYHA分级类别中一致改善6MWD、分层复合终点,并降低CRP和NT-proBNP(交互P均无统计学意义)。
临床怎么用
- 对于肥胖相关HFpEF患者,司美格鲁肽2.4 mg每周一次可考虑用于改善NYHA功能分级及心衰相关症状和运动能力。
- NYHA III/IV级患者可能从司美格鲁肽获得的健康状态改善幅度更大。
- 司美格鲁肽对体重、6MWD、炎症和充血生物标志物的改善不受基线NYHA分级影响。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms, physical limitations, and exercise function, and reduced bodyweight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Whether semaglutide improves functional status, as assessed by NYHA functional class, is unknown. OBJECTIVES: The goal of this study was to examine the effects of semaglutide on change in NYHA functional class over time. We also investigated the effects of semaglutide on HF-related symptoms, physical limitations, and bodyweight and other trial endpoints across baseline NYHA functional class categories. METHODS: This was a prespecified analysis of pooled data from 2 international, double-blind, randomized trials (STEP-HFpEF and STEP-HFpEF type 2 diabetes [STEP-HFpEF DM], comprising the STEP-HFpEF program), which collectively randomized 1,145 participants with obesity-related HFpEF to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. The outcome of interest for this analysis was the change in NYHA functional class (baseline to 52 weeks). We also investigated the effects of semaglutide on the dual primary, confirmatory secondary, and selected exploratory endpoints according to baseline NYHA functional class. RESULTS: More semaglutide-treated than placebo-treated patients had an improvement in NYHA functional class (32.6% vs 21.5%, respectively; OR: 2.20 [95% CI: 1.62-2.99; P < 0.001]) and fewer semaglutide-treated patients experienced deterioration in NYHA functional class (2.09% vs 5.24%, respectively; OR: 0.36 [95% CI: 0.19-0.70; P = 0.003]) at 52 weeks. Semaglutide (vs placebo) improved the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CCS) across NYHA functional class categories; this was especially pronounced in those in NYHA functional classes III/IV (10.5 points [95% CI: 6.6-14.4 points]) vs NYHA functional class II (6.0 points [95% CI: 3.4-8.6 points]) (P interaction = 0.06). By contrast, the degree of reduction in bodyweight was similar with semaglutide vs placebo regardless of baseline NYHA functional class category (NYHA functional class II, -8.4% [95% CI: -9.4% to -7.3%]; NYHA functional classes III/IV, -8.3% [95% CI: -9.9% to -6.8%]; P interaction = 0.96). Semaglutide consistently improved 6-minute walking distance (6MWD), the hierarchical composite endpoint (death, HF events, differences in KCCQ-CSS, and 6MWD changes), and reduced C-reactive protein and N-terminal prohormone of brain natriuretic peptide across NYHA functional class categories (all P interactions = NS). CONCLUSIONS: In patients with obesity-related HFpEF, fewer semaglutide-treated than placebo-treated patients had a deterioration, and more had an improvement, in NYHA functional class at 52 weeks. Semaglutide consistently improved HF-related symptoms, physical limitations, and exercise function, and reduced bodyweight and biomarkers of inflammation and congestion in all NYHA functional class categories. Semaglutide-mediated improvements in health status were especially large in patients with NYHA functional classes III/IV. (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure and Obesity; NCT04788511) (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes; NCT04916470).
引用
- Schou, Petrie, Borlaug, et al. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program. J Am Coll Cardiol. 2024. PMID: 38913004. doi:10.1016/j.jacc.2024.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。